Abstract
Aim:
To screen the selective inhibitors for human cyclooxygenase-2 ((h)COX-2) utilizing molecular simulation.
Methods:
Eight xanthone derivatives, compounds A-H, were employed by the structure-based research methodology. Resveratrol and NS-398 were selected as the control compounds for COX-1 and COX-2, respectively. The docking results were scored and the interaction energies of the complexes were calculated by CHARMm forcefield.
Results:
NS-398 could not dock into the active site of COX-1. However, resveratrol, the specific selective compound for COX-1, gained lower interaction energy while docked in COX-1. The lower interaction energies were investigated, while compound B and F were docked into the catalytic sites of COX-1 and COX-2, respectively. Compound A, 1,3,6,7-tetrahydroxyxanthone, revealed high inhibitory potency to both COX-1 and COX-2.
Conclusion:
The conformations of the docking would influence the values of interaction energies. The hydrogen bond could also increase the stability of the whole complex, which might suggest that compound B had a suitable conformation in the tunnel-like active site of COX-1. Compound F, a potent agent for COX-2, revealed a strong hydrogen bond with Ser516 in human COX-2 to form a stable complex.
Similar content being viewed by others
Article PDF
References
Li L, Pettit AR, Gregory LS, Forwood MR . Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name. Cytokine Growth Factor Rev 2006; 17: 203–16.
Tsai A, Kulmacz RJ, Palmer G . Spectroscopic evidence for reaction of prostaglandin H synthase-1 tyrosyl radical with arachidonic acid. J Biol Chem 1995; 270: 10 503–8.
Kulmacz RJ . Regulation of cyclooxygenase catalysis by hydroperoxides. Biochem Biophys Res Commun 2005; 338: 25–33.
Shimamoto C, Nakanishi Y, Katsu K, Nakano T, Kubota T, Mori H, et al. Prostaglandin E2 release in gastric antral mucosa of guinea-pigs: basal PGE2 release by cyclo-oxygenase 2 and ACh-stimulated PGE2 release by cyclo-oxygenase 1. Exp Physiol 2006; 91: 1015–24.
Konturek PC, Konturek SJ, Bielanski W, Kania J, Zuchowicz M, Hartwich A, et al. Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients. Dig Dis Sci 2003; 48: 2005–17.
Zhang WY, Yang XN, Jin DZ, Zhu XZ . Expression and enzyme activity determination of human cyclooxygenase-1 and -2 in a baculovirus-insect cell system. Acta Pharmacol Sin 2004; 25: 1000–6.
Stoll G, Bendszus M . Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006; 37: 1923–32.
Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF . Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin 2004; 25: 927–31.
Kundu N, Fulton AM . Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002; 62: 2343–6.
Chen PY, Long QC . Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta Pharmacol Sin 2004; 25: 943–9.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN . Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705–16.
Lora M, Denault JB, Leduc R, de Brum-Fernandes AJ . Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids 1998; 59: 55–62.
Stone E . An account of the success of the bark of the willow in the cure of agues. Phil Trans 1763; 53: 195–200.
Hao LL, Mei QB, Zhang BL, Jia M, Li XQ, Zhang F . PC-407 inhibited proliferation and induced apoptosis in human colon cancer SW-1116 cells. Acta Pharmacol Sin 2004; 25: 1509–14.
Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 293–7.
Kurumbail RG, Kiefer JR, Marnett LJ . Cyclooxygenase enzymes: catalysis and inhibition. Curr Opin Struct Biol 2001; 11: 752–60.
Wong E, Bayly C, Waterman HL, Riendeau D, Mancini JA . Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 right-arrow Arg and Ile523 right-arrow val mutation. J Biol Chem 1997; 272: 9280–6.
Li XH, Li JJ, Zhang HW, Sun P, Zhang YL, Cai SH, et al. Nimesulide inhibits tumor growth in mice implanted hepatoma: overexpression of Bax over Bcl-2. Acta Pharmacol Sin 2003; 24: 1045–50.
Colin-Jones DG . Drug-induced gastrointestinal ulceration: a review. J R Soc Med 1980; 73: 46–7.
Laine L, Maller ES, Yu C, Quan H, Simon T . Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127: 395–402.
Niederberger E, Manderscheid C, Geisslinger G . Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Biochem Biophys Res Commun 2006; 342: 940–8.
Yoshimi N, Shimizu M, Matsunaga K, Yamada Y, Fujii K, Hara A, et al. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitro-phenyl)methane sulfonamide (NS-398), a selective cyclooxygen-ase-2 inhibitor, in rat colon carcinogenesis induced by azoxy-methane. Jpn J Cancer Res 1999; 90: 406–12.
Szewczuk LM, Forti L, Stivala LA, Penning TM . Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004; 279: 22 727–37.
Matsumoto K, Akao Y, Kobayashi E, Ohguchi K, Ito T, Tanaka T, et al. Induction of apoptosis by xanthones from mangosteen in human leukemia cell lines. J Nat Prod 2003; 66: 1124–7.
Ho CK, Huang YL, Chen CC . Garcinone E, a xanthone derivative, has potent cytotoxic effect against hepatocellular carcinoma cell lines. Planta Med 2002; 68: 975–9.
Moongkarndi P, Kosem N, Kaslungka S, Luanratana O, Pongpan N, Neungton N . Antiproliferation, antioxidation and induction of apoptosis by Garcinia mangostana (mangosteen) on SKBR3 human breast cancer cell line. J Ethnopharmacol 2004; 90: 161–6.
Nabandith V, Suzui M, Morioka T, Kaneshiro T, Kinjo T, Matsumoto K, et al. Inhibitory effects of crude alpha-mangostin, a xanthone derivative, on two different categories of colon preneoplastic lesions induced by 1, 2-dimethylhydrazine in the rat. Asian Pac J Cancer Prev 2004; 5: 433–8.
Nakatani K, Nakahata N, Arakawa T, Yasuda H, Ohizumi Y . Inhibition of cyclooxygenase and prostaglandin E2 synthesis by gamma-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. Biochem Pharmacol 2002; 63: 73–9.
Venkatachalam CM, Jiang X, Oldfield T, Waldman M . LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 2003; 21: 289–307.
Gehlhaar DK, Verkhivker GM, Rejto PA, Sherman CJ, Fogel DB, Fogel LJ, et al. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem Biol 1995; 2: 317–24.
Muegge I, Martin YC . A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J Med Chem 1999; 42: 791–804.
Selvam C, Jachak SM, Gnana Oli R, Thilagavathi R, Chakraborti AK, Bhutani KK . A new cyclooxygenase (COX) inhibitory pterocarpan from Indigofera aspalathoides: structure elucidation and determination of binding orientations in the active sites of the enzyme by molecular docking. Tetrahedron Lett 2004; 45: 4311–4.
Gupta K, Selinsky BS, Kaub CJ, Katz AK, Loll PJ . The 2.0 A resolution crystal structure of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase. J Mol Biol 2004; 335: 503–18.
Kiefer JR, Pawlitz JL, Moreland KT, Stegeman RA, Hood WF, Gierse JK, et al. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 2000; 405: 97–101.
Filizola M, Perez JJ, Palomer A, Mauleon D . Comparative molecular modeling study of the three-dimensional structures of prostaglandin endoperoxide H2 synthase 1 and 2 (COX-1 and COX-2). J Mol Graph Model 1997; 15: 290–300.
Allinger NL . Conformational analysis 130.MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J Am Chem Soc 1977; 99: 8127–34.
De Witt DL . Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 1999; 55: 625–31.
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was supported by grants from the National Science Council of China (NSC 94-2213-E-039-002) and China Medical University (CMU95-033, CMU95-156, and CMU95-239).
Rights and permissions
About this article
Cite this article
Chen, Yc., Chen, Kt. Novel selective inhibitors of hydroxyxanthone derivatives for human cyclooxygenase-2. Acta Pharmacol Sin 28, 2027–2032 (2007). https://doi.org/10.1111/j.1745-7254.2007.00663.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00663.x
Keywords
This article is cited by
-
Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study
Journal of Molecular Modeling (2010)
-
Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis
Acta Pharmacologica Sinica (2009)